Compare MLKN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | CTMX |
|---|---|---|
| Founded | 1905 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | 1994 | 2015 |
| Metric | MLKN | CTMX |
|---|---|---|
| Price | $15.45 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 625.8K | ★ 2.8M |
| Earning Date | 03-25-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | $76,201,000.00 |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | $7.61 |
| P/E Ratio | ★ $15.74 | $22.58 |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $1.72 |
| 52 Week High | $23.18 | $8.21 |
| Indicator | MLKN | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 39.49 |
| Support Level | $15.36 | $3.39 |
| Resistance Level | $16.34 | $3.91 |
| Average True Range (ATR) | 0.57 | 0.20 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 57.63 | 39.76 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.